401 related articles for article (PubMed ID: 16253563)
1. Superior virulence of Mycobacterium bovis over Mycobacterium tuberculosis (Mtb) for Mtb-resistant and Mtb-susceptible mice is manifest as an ability to cause extrapulmonary disease.
Medina E; Ryan L; LaCourse R; North RJ
Tuberculosis (Edinb); 2006 Jan; 86(1):20-7. PubMed ID: 16253563
[TBL] [Abstract][Full Text] [Related]
2. Haemolytic activity of Mycobacterium spp.
Brzychcy M; Andrzejczyk Z; Zalewska N; Zwolska Z; Rudnicka W
Acta Microbiol Pol; 1997; 46(4):377-85. PubMed ID: 9516984
[TBL] [Abstract][Full Text] [Related]
3. Development of infection model for studying intracellular gene expression of Mycobacterium tuberculosis.
Alli OA; Ogbolu DO; Spreadbury CL
Afr J Med Med Sci; 2009 Dec; 38(4):325-32. PubMed ID: 20499625
[TBL] [Abstract][Full Text] [Related]
4. Granuloma formation in severe combined immunodeficient (SCID) mice in response to progressive BCG infection. Tendency not to form granulomas in the lung is associated with faster bacterial growth in this organ.
North RJ; Izzo AA
Am J Pathol; 1993 Jun; 142(6):1959-66. PubMed ID: 8506962
[TBL] [Abstract][Full Text] [Related]
5. Virulence ranking of some Mycobacterium tuberculosis and Mycobacterium bovis strains according to their ability to multiply in the lungs, induce lung pathology, and cause mortality in mice.
Dunn PL; North RJ
Infect Immun; 1995 Sep; 63(9):3428-37. PubMed ID: 7642273
[TBL] [Abstract][Full Text] [Related]
6. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination.
Pethe K; Alonso S; Biet F; Delogu G; Brennan MJ; Locht C; Menozzi FD
Nature; 2001 Jul; 412(6843):190-4. PubMed ID: 11449276
[TBL] [Abstract][Full Text] [Related]
7. Development of a Mycobacterium bovis intranasal challenge model in mice.
Logan KE; Gavier-Widen D; Hewinson RG; Hogarth PJ
Tuberculosis (Edinb); 2008 Sep; 88(5):437-43. PubMed ID: 18590980
[TBL] [Abstract][Full Text] [Related]
8. Differences in the ability to generate type 1 T helper cells need not determine differences in the ability to resist Mycobacterium tuberculosis infection among mouse strains.
Jung YJ; Ryan L; LaCourse R; North RJ
J Infect Dis; 2009 Jun; 199(12):1790-6. PubMed ID: 19426112
[TBL] [Abstract][Full Text] [Related]
9. Histopathogenesis of experimental Mycobacterium bovis infection in mice.
Chambers MA; Gavier-Widen D; Hewinson RG
Res Vet Sci; 2006 Feb; 80(1):62-70. PubMed ID: 15922378
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of membrane TNF mediated host resistance is dependent on mycobacterial virulence.
Dambuza I; Allie N; Fick L; Johnston N; Fremond C; Mitchell J; Quesniaux VF; Ryffel B; Jacobs M
Tuberculosis (Edinb); 2008 May; 88(3):221-34. PubMed ID: 17950671
[TBL] [Abstract][Full Text] [Related]
11. Growth of a highly virulent strain of Mycobacterium tuberculosis in mice of differing susceptibility to tuberculous challenge.
Kelley CL; Collins FM
Tuber Lung Dis; 1999; 79(6):367-70. PubMed ID: 10694981
[TBL] [Abstract][Full Text] [Related]
12. Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guérin (BCG) in infected mice.
Kohama H; Umemura M; Okamoto Y; Yahagi A; Goga H; Harakuni T; Matsuzaki G; Arakawa T
Vaccine; 2008 Feb; 26(7):924-32. PubMed ID: 18192091
[TBL] [Abstract][Full Text] [Related]
13. Strain-related virulence of the dominant Mycobacterium tuberculosis strain in the Canadian province of Manitoba.
Petrelli D; Kaushal Sharma M; Wolfe J; Al-Azem A; Hershfield E; Kabani A
Tuberculosis (Edinb); 2004; 84(5):317-26. PubMed ID: 15207807
[TBL] [Abstract][Full Text] [Related]
14. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells.
Badell E; Nicolle F; Clark S; Majlessi L; Boudou F; Martino A; Castello-Branco L; Leclerc C; Lewis DJ; Marsh PD; Gicquel B; Winter N
Vaccine; 2009 Jan; 27(1):28-37. PubMed ID: 18977269
[TBL] [Abstract][Full Text] [Related]
15. Antibody bound to the surface antigen MPB83 of Mycobacterium bovis enhances survival against high dose and low dose challenge.
Chambers MA; Gavier-Widén D; Hewinson RG
FEMS Immunol Med Microbiol; 2004 Jun; 41(2):93-100. PubMed ID: 15145452
[TBL] [Abstract][Full Text] [Related]
16. Combination of host susceptibility and virulence of Mycobacterium tuberculosis determines dual role of nitric oxide in the protection and control of inflammation.
Beisiegel M; Kursar M; Koch M; Loddenkemper C; Kuhlmann S; Zedler U; Stäber M; Hurwitz R; Kaufmann SH
J Infect Dis; 2009 Apr; 199(8):1222-32. PubMed ID: 19302011
[TBL] [Abstract][Full Text] [Related]
17. PE_PGRS30 is required for the full virulence of Mycobacterium tuberculosis.
Iantomasi R; Sali M; Cascioferro A; Palucci I; Zumbo A; Soldini S; Rocca S; Greco E; Maulucci G; De Spirito M; Fraziano M; Fadda G; Manganelli R; Delogu G
Cell Microbiol; 2012 Mar; 14(3):356-67. PubMed ID: 22050772
[TBL] [Abstract][Full Text] [Related]
18. Evidence inconsistent with a role for the Bcg gene (Nramp1) in resistance of mice to infection with virulent Mycobacterium tuberculosis.
Medina E; North RJ
J Exp Med; 1996 Mar; 183(3):1045-51. PubMed ID: 8642246
[TBL] [Abstract][Full Text] [Related]
19. Establishment of an in vitro model using NR8383 cells and Mycobacterium bovis Calmette-Guerin that mimics a chronic infection of Mycobacterium tuberculosis.
Hino M; Oda M; Yoshida A; Nakata K; Kohchi C; Nishizawa T; Inagawa H; Hori H; Makino K; Terada H; Soma G
In Vivo; 2005; 19(5):821-30. PubMed ID: 16097433
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and protection induced by Mycobacterium tuberculosis mce-2 and mce-3 mutants in a Balb/c mouse model of progressive pulmonary tuberculosis.
Aguilar LD; Infante E; Bianco MV; Cataldi A; Bigi F; Pando RH
Vaccine; 2006 Mar; 24(13):2333-42. PubMed ID: 16388878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
